Meyka Pro banner
SI-BONE, Inc.

SI-BONE, Inc. Fundamental Analysis (NASDAQ: SIBN)

SIBN●NASDAQ
HealthcareMedical - Devices
$25.60
$1.36(5.61%)
U.S. Market opens in 15h 50m

SI-BONE, Inc. Fundamental Analysis (NASDAQ: SIBN)

SI-BONE, Inc. (NASDAQ: SIBN) shows moderate financial fundamentals with a PE ratio of -77.79, profit margin of -6.20%, and ROE of -7.57%. The company generates $0.2B in annual revenue with strong year-over-year growth of 20.19%.

Key Strengths

Cash Position12.73%
PEG Ratio-1.40
Current Ratio7.58

Areas of Concern

ROE-7.57%
Operating Margin-7.57%
We analyze SIBN's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 35.3/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
35.3/100

We analyze SIBN's fundamental strength across five key dimensions:

Efficiency Score

Weak

SIBN struggles to generate sufficient returns from assets.

ROA > 10%
-5.33%

Valuation Score

Excellent

SIBN trades at attractive valuation levels.

PE < 25
-77.79
PEG Ratio < 2
-1.40

Growth Score

Excellent

SIBN delivers strong and consistent growth momentum.

Revenue Growth > 5%
20.19%
EPS Growth > 10%
41.33%

Financial Health Score

Excellent

SIBN maintains a strong and stable balance sheet.

Debt/Equity < 1
0.23
Current Ratio > 1
7.58

Profitability Score

Weak

SIBN struggles to sustain strong margins.

ROE > 15%
-756.87%
Net Margin ≥ 15%
-6.20%
Positive Free Cash Flow
No

Key Financial Metrics

Is SIBN Expensive or Cheap?

P/E Ratio

SIBN trades at -77.79 times earnings. This suggests potential undervaluation.

-77.79

PEG Ratio

When adjusting for growth, SIBN's PEG of -1.40 indicates potential undervaluation.

-1.40

Price to Book

The market values SI-BONE, Inc. at 5.86 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

5.86

EV/EBITDA

Enterprise value stands at -274.54 times EBITDA. This is generally considered low.

-274.54

How Well Does SIBN Make Money?

Net Profit Margin

For every $100 in sales, SI-BONE, Inc. keeps $-6.20 as profit after all expenses.

-6.20%

Operating Margin

Core operations generate -7.57 in profit for every $100 in revenue, before interest and taxes.

-7.57%

ROE

Management delivers $-7.57 in profit for every $100 of shareholder equity.

-7.57%

ROA

SI-BONE, Inc. generates $-5.33 in profit for every $100 in assets, demonstrating efficient asset deployment.

-5.33%

Following the Money - Real Cash Generation

Operating Cash Flow

SI-BONE, Inc. generates limited operating cash flow of $6.07M, signaling weaker underlying cash strength.

$6.07M

Free Cash Flow

SI-BONE, Inc. generates weak or negative free cash flow of $-4.19M, restricting financial flexibility.

$-4.19M

FCF Per Share

Each share generates $-0.09 in free cash annually.

$-0.09

FCF Yield

SIBN converts -0.38% of its market value into free cash.

-0.38%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-77.79

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-1.40

vs 25 benchmark

P/B Ratio

Price to book value ratio

5.86

vs 25 benchmark

P/S Ratio

Price to sales ratio

4.90

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.23

vs 25 benchmark

Current Ratio

Current assets to current liabilities

7.58

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.08

vs 25 benchmark

ROA

Return on assets percentage

-0.05

vs 25 benchmark

ROCE

Return on capital employed

-0.07

vs 25 benchmark

How SIBN Stacks Against Its Sector Peers

MetricSIBN ValueSector AveragePerformance
P/E Ratio-77.7930.84 Better (Cheaper)
ROE-7.57%573.00% Weak
Net Margin-6.20%5349.00% Weak
Debt/Equity0.23-0.03 (disorted) Distorted
Current Ratio7.585.76 Strong Liquidity
ROA-5.33%-254.00% (disorted) Weak

SIBN outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews SI-BONE, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

82.87%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

71.10%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

98.53%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ